Compare ARLO & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | LBRX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2018 | 2025 |
| Metric | ARLO | LBRX |
|---|---|---|
| Price | $12.36 | $37.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $21.00 | ★ $57.30 |
| AVG Volume (30 Days) | ★ 1.2M | 337.4K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | 98.22 |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.76 | N/A |
| Revenue Next Year | $5.56 | N/A |
| P/E Ratio | $75.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.05 | $14.32 |
| 52 Week High | $19.94 | $50.16 |
| Indicator | ARLO | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 40.51 |
| Support Level | $12.23 | $26.75 |
| Resistance Level | $14.01 | $49.74 |
| Average True Range (ATR) | 0.47 | 2.09 |
| MACD | -0.06 | -0.27 |
| Stochastic Oscillator | 32.87 | 37.63 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. Its cloud-based platform provides users with visibility, insight, and a powerful means to help protect and connect in real-time with the people and things that matter, from any location with a Wi-Fi or cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.